Casey KA, Smith MA, Sinibaldi D, et al. - In this study, the ability of anifrolumab, a type I interferon (IFN) receptor–blocking antibody, to reduce neutrophil extracellular trap formation and modulate cardiometabolic disease markers relative to placebo was assessed. Researchers collected blood samples pre‐ and post‐dose from patients with moderate to severe SLE enrolled in the phase 2b MUSE trial. They compared a total of 305 baseline samples with healthy controls and post‐treatment samples in anifrolumab 300‐mg (n=99) and placebo groups (n=102). This study's findings revealed a key role for type I IFNs in modulating factors contributing to SLE vasculopathy and imply that inhibiting this pathway could reduce cardiovascular risk in these patients.